Skip to content
Menu

Roivant Sciences Ltd. ROIV

Full chart Compare
Set alert

Price alert · ROIV

All alert types
38.66 USD -0.30 (-0.78%)

Regular-session close

38.68 +0.02 +0.06%

After hours · Nov 20, 6:34 PM ET

38.46 Day range 39.51
19.96 52-week range 42.50
YTD
+78.13%
1 year
+90.70%

5D -0.69 (-1.72%)

383940MonTueWedThuFri39.32
Market cap
28.01B
Revenue (ttm)
41.08M
EPS (ttm)
-0.65
Shares out
724.56M
Forward P/E
-26.98
YTD return
+78.13%
1-year return
+90.70%
50-day average
37.22
200-day average
32.65
Enterprise value
24.70B
Volume
3.97M
Avg volume
8.16M
Open
38.86
Previous close
38.96
Day's range
38.46 – 39.51
52-week range
19.96 – 42.50
Beta
1.20
Analysts
Strong Buy
Price target
50.82 (+31.5%)
Earnings date
Feb 5, 2027

Key statistics

Price / sales
681.76
Price / book
6.96
Revenue growth
2135.60%
Free cash flow
-358.86M
Total cash
4.21B
Total debt
106.57M
Return on equity
-8.54%
Short % of float
8.52%

Fundamental scorecard

4 of 25 checks passed on ROIV’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ROIV Revenue — quarterly 35.12M
ROIV Net income — quarterly -191.62M
ROIV EPS — quarterly -0.27

Earnings

ROIV recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 5, 2027Dec 30, 2026-0.36———
Nov 9, 2026Sep 30, 2026-0.36664-0.27+0.10+26.36%
Aug 6, 2026Jun 30, 2026-0.29962-0.33-0.03-10.14%
May 20, 2026Mar 31, 2026-0.28931-0.2792+0.01+3.49%
Feb 6, 2026Dec 31, 2025-0.29954-0.24+0.06+19.88%
Nov 10, 2025Sep 30, 2025-0.3198-0.20193+0.12+36.86%

Upgrades / downgrades

ROIV analyst upgrades and downgrades
DateFirmActionFromTo
Nov 10, 2026HC Wainwright & Co.mainBuyBuy
Oct 28, 2026CitigroupmainBuyBuy
Oct 12, 2026Wolfe ResearchdownOutperformPeer Perform
Sep 17, 2026Stifelinit—Buy
Sep 9, 2026TD CowenmainBuyBuy
Sep 9, 2026GuggenheimmainBuyBuy

About Roivant Sciences Ltd.

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

Sector
Healthcare
Industry
Biotechnology
Country
United Kingdom
Website
roivant.com

News

Your note

Sign in to keep a note on ROIV — it syncs with the Stock Master app.

Insider holders

ROIV insider holders
InsiderRelationLatest transactionDateShares held
GLINE MATTHEWChief Executive OfficerSaleApr 15, 202616,736,100
GOLD DANIEL ALLENDirectorSaleNov 16, 20260
KUMAR RAKHIOfficerConversion of Exercise of derivative securityFeb 12, 2025163,264
MANCHESTER KEITH SDirectorSaleNov 16, 20260
OREN ILANDirectorStock Award(Grant)Oct 22, 2026124,490
PULIK RICHARDChief Financial OfficerConversion of Exercise of derivative securityNov 10, 2026222,046

Institution ownership

ROIV institution ownership
Holder% heldSharesValueReported
FMR, LLC11.81%85,575,5533.31BSep 29, 2026
Blackrock Inc.8.54%61,879,2322.39BSep 29, 2026
Morgan Stanley5.33%38,603,6061.49BSep 29, 2026
QVT Financial LP3.27%23,723,074917.02MSep 29, 2026
Vanguard Capital Management LLC3.19%23,127,563894.00MSep 29, 2026
State Street Corporation3.09%22,399,587865.86MSep 29, 2026

Fund ownership

ROIV fund ownership
Holder% heldSharesValueReported
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund3.22%23,359,928902.98MSep 29, 2026
iShares Trust-iShares Core S&P Mid-Cap ETF2.66%19,297,013745.93MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.21%15,987,737618.01MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund1.59%11,546,280446.32MJun 29, 2026
Invesco Exchange-Traded Fund Trust-Invesco S&P MidCap Momentum ETF0.95%6,900,746266.75MSep 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund0.93%6,740,514260.55MSep 29, 2026